133 related articles for article (PubMed ID: 31030485)
1. RAS Mutation in Mucinous Carcinoma of the Ovary.
Panyavaranant P; Teerapakpinyo C; Pohthipornthawat N; Oranratanaphan S; Shuangshoti S; Triratanachat S
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1127-1132. PubMed ID: 31030485
[TBL] [Abstract][Full Text] [Related]
2. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
3. Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component.
Li X; Sun K; Liao X; Gao H; Zhu H; Xu R
BMC Cancer; 2020 May; 20(1):400. PubMed ID: 32384877
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
5. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
8. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
10. Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.
Genestie C; Auguste A; Al Battal M; Scoazec JY; Gouy S; Lacroix L; Morice P; Pautier P; Leary A; Devouassoux-Shisheboran M
Virchows Arch; 2021 May; 478(5):885-891. PubMed ID: 33009577
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
12. Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran.
Koochak A; Rakhshani N; Karbalaie Niya MH; Tameshkel FS; Sohrabi MR; Babaee MR; Rezvani H; Bahar B; Imanzade F; Zamani F; Khonsari MR; Ajdarkosh H; Hemmasi G
Asian Pac J Cancer Prev; 2016; 17(2):603-8. PubMed ID: 26925650
[TBL] [Abstract][Full Text] [Related]
13. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
14. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
[TBL] [Abstract][Full Text] [Related]
15. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J
Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203
[TBL] [Abstract][Full Text] [Related]
16. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.
Lee YJ; Lee MY; Ruan A; Chen CK; Liu HP; Wang CJ; Chao WR; Han CP
Oncotarget; 2016 Dec; 7(50):82097-82103. PubMed ID: 27888800
[TBL] [Abstract][Full Text] [Related]
17. Mucinous borderline ovarian tumors with BRAF
Ohnishi K; Nakayama K; Ishikawa M; Ishibashi T; Yamashita H; Nakamura K; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Arch Gynecol Obstet; 2020 Aug; 302(2):487-495. PubMed ID: 32556513
[TBL] [Abstract][Full Text] [Related]
18. Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.
Chay WY; Kwok LL; Tiong WN; Krisna SS; Lim KH; Iyer NG; Goh LK; Tan DS
Int J Gynecol Cancer; 2018 Mar; 28(3):428-436. PubMed ID: 29465505
[TBL] [Abstract][Full Text] [Related]
19. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
20. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
